Navigation Links
Both Overtreatment and Undertreatment of Patients with High Blood Pressure Linked to Kidney Failure and Death
Date:8/4/2014

PASADENA, Calif., Aug. 4, 2014 /PRNewswire/ -- The mantra for treatment for high blood pressure has been "the lower, the better," but that goal can potentially put patients at risk of kidney failure or death, according to a Kaiser Permanente study published today in the Journal of the American College of Cardiology.

Researchers examined the electronic health records of nearly 400,000 Kaiser Permanente patients in Southern California who were taking medications to treat high blood pressure from January 2006 through December 2010. They found that:

  • Patients within the range between 130 and 139 systolic and between 60 and 79 diastolic blood pressure were at the lowest risk for kidney failure and death.
  • Those who achieved a blood pressure outside of that range, either above or below, were more likely to have increased health risks.
  • Patients who had a systolic blood pressure in the range between 120 and 129 (widely accepted as normal) were 10 percent more likely than those who had a systolic blood pressure between 130 and 139 to die or develop kidney failure.
  • Patients who had a systolic blood pressure between 140 and 149 were 40 percent more likely than those who had a systolic rate between 130 and 139 to die or develop kidney failure.

"Physicians have often emphasized the need to bring a patient's blood pressure down as low as possible for the best outcomes," said lead study author John J. Sim, MD, Kaiser Permanente Los Angeles Medical Center. "However, the findings of our study suggest that treating patients with high blood pressure too aggressively may potentially lead to poor health outcomes."

The results of this study also demonstrate a need to better understand the ideal target blood pressure ranges as well as the potential dangers of overtreating patients, according to the researchers.

"We hope our findings will pave the way for a more effective strategy in treating high blood pressure," said Dr. Sim. "Through personalized treatment plans, we can minimize the lifestyle burden on patients and improve the safety of their treatment regimens, while reducing the cost to both patients and the health care system as a whole."

According to National Institutes of Health, one in three people in the United States has high blood pressure, costing almost $94 billion in health care services, medications and missed days of work. High blood pressure can also lead to an array of complications, including kidney damage, heart disease and stroke. Although current treatment guidelines recommend that adults between 30 and 59 years old with hypertension should aim for a target blood pressure below 140 systolic and 90 diastolic, they do not refer to the dangers of having a patient's blood pressure drop below a certain level. Additional research could lead to more accurate guidelines aimed at safeguarding patient health.

Kaiser Permanente is a national leader in reducing and preventing heart attacks and strokes. Both Kaiser Permanente Colorado (2012) and Kaiser Permanente Northern California (2013) have been recognized by the U.S. Department of Health and Human Services as Hypertension Control Champions by Million Hearts™. Additionally, Kaiser Permanente Northern California boosted its hypertension control rate from 44 percent to 80 percent over an eight-year period by using many best-performing clinical practices, such as establishing a hypertension registry, improving medication adherence with email and phone reminders, and making blood pressure measurement readily available.

This study was supported by Kaiser Permanente Southern California Regional Research and a research grant from the National Institute of Diabetes, Digestive and Kidney Disease (R01 DK078106). Additional support was provided by the National Institutes of Health grants K24-DK091419 and R01-DK096920.

Other authors of the paper include: Jiaxiao Shi, PhD, and Steven J. Jacobsen, MD, PhD,   Kaiser Permanente Southern California, Department of Research & Evaluation; Csaba P. Kovesdy, MD, Memphis VA Medical Center; Kamyar Kalantar-Zadeh, MD, PhD, University of California Irvine Medical Center, Division of Nephrology and Hypertension.

About the Kaiser Permanente Southern California Department of Research & Evaluation
The Department of Research & Evaluation conducts high-quality, innovative research into disease etiology, prevention, treatment and care delivery. Investigators conduct epidemiology, health sciences and behavioral research as well as clinical trials. Areas of interest include diabetes and obesity, cancer, HIV/AIDS, cardiovascular disease, aging and cognition, pregnancy outcomes, women's and children's health, quality and safety, and pharmacoepidemiology. Located in Pasadena, Calif., the department focuses on translating research to practice quickly to benefit the health and lives of Kaiser Permanente Southern California members and the general population. Visit kp.org/research.

About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve approximately 9.3 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/share

For more information:
Samantha Purzak, spurzak@golin.com, 202.585.2603
Sandra Hernandez-Millett, sandra.d.hernandez-millett@kp.org, 626.405.5384

Logo - http://photos.prnewswire.com/prnh/20130718/SF49717LOGO


'/>"/>
SOURCE Kaiser Permanente
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Phreesia identifies over 26% of patients who require additional autism evaluation
4. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
5. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
6. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
7. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
8. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
9. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
(Date:4/28/2016)... 28, 2016 Research and Markets ... Surgery Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is ... the period 2016-2020. , ,The growing adoption of laser ... growth of the market. Lasers are used to treat ...
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... 02, 2016 , ... Over $60 Billion is spent annually on products for ... leading product review site for Toys, Tots, Pets & More (TTPM) announced the 15 ... Showcase at the Metropolitan Pavilion in New York City. , Chosen from a field ...
(Date:5/2/2016)... , ... May 02, 2016 , ... This week Omega ... its 2016 guest season which runs through October. Omega is offering a record 370 ... , “There has never been such widespread interest in or need for the ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist in Orange County, ... According to the research, which was published in the “Journal of the American Geriatrics ... about 5.4 million Americans have Alzheimer’s disease. The study found that dental problems may ...
(Date:5/2/2016)... RICHEY, Fla. (PRWEB) , ... ... ... and medical researchers report that many commonly used prescription medications, including anxiolytics, ... (1). To mitigate these risks, Novus Medical Detox Center —a leading ...
(Date:5/2/2016)... ... May 02, 2016 , ... The ... be held at the Bellagio Hotel in Las Vegas, NV from October 17–19, ... will be co-hosting the event. , This year’s conference will offer presentations ...
Breaking Medicine News(10 mins):